Summary & Overview
HCPCS J1840: Injection, kanamycin sulfate, up to 500 mg
HCPCS Level II code J1840 denotes the parenteral administration of kanamycin sulfate, up to 500 mg. As a single-drug injectable code, J1840 is used in billing for acute or outpatient antibiotic therapy when kanamycin is selected by clinicians. Nationally, use of this code reflects inpatient and outpatient administration patterns for aminoglycoside antibiotics and carries implications for facility billing workflows and pharmacy supply chains.
Key payers addressed in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise account of what the code represents, typical settings where the service is delivered, and the clinical context for parenteral antibiotic use. The analysis provides benchmarks and payment context where available, summaries of common modifiers used with injectable drug codes, and operational notes relevant to sites that administer parenteral antibiotics. Policy updates and payer coverage patterns affecting injectable drug billing and reimbursement are summarized at a national level.
This publication is intended for billing managers, revenue cycle staff, pharmacy directors, and clinicians who need a clear, operational summary of HCPCS Level II code J1840 and the administrative considerations tied to kanamycin injection services.
Billing Code Overview
HCPCS Level II code J1840 represents an injection of kanamycin sulfate, up to 500 mg. The service type is an injectable antibiotic administration intended for parenteral treatment of infections where kanamycin is indicated.
Typical site of service is an inpatient or outpatient clinical setting where parenteral antibiotics are administered, such as hospitals, infusion centers, emergency departments, or other licensed acute care settings.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a severe Gram-negative or mycobacterial infection for which first-line agents are contraindicated or have failed, requiring parenteral aminoglycoside therapy with J1840 (kanamycin sulfate, up to 500 mg). The patient presents to an outpatient infusion clinic, hospital ward, or skilled nursing facility for administration. Initial evaluation includes review of culture and sensitivity data, baseline renal function (serum creatinine, BUN), baseline audiology or vestibular assessment if indicated, and measurement of serum drug levels when part of institutional protocol. The clinical workflow: order placed by the prescribing clinician; pharmacy prepares the appropriate dose of kanamycin sulfate; nursing verifies patient identity, obtains baseline vital signs and relevant labs, confirms allergies, and performs administration per facility protocol (intramuscular or intravenous route as appropriate). Post-administration monitoring includes assessment for signs of nephrotoxicity and ototoxicity, repeat renal function testing at intervals, and documentation of lot number, dose, route, and site. If adverse effects occur or treatment goals are met before planned course completion, the clinician may discontinue the infusion and document reason; applicable modifiers may be appended to the claim to indicate unusual circumstances or professional billing nuances.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services |